FindTrial
Sign In

The Pharmacogenomic Study of Hydromorphone and Sufentanil

Interindividual Variations of Hydromorphone’s and Sufentanil’s Drug Responses in Perioperative Period

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021991
Enrollment
Unknown
Registered
2019-03-19
Start date
2019-01-30
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Group Hydromorphone:postoperative patient controlled analgesia with Hydromorphone
Group Sufentanil:postoperative patient controlled analgesia with Sufentanil

Sponsors

The First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective abdominal surgery; 2. Male or female over 18 years old; 3. Patients undergoing general anesthesia(ASA I-III).

Exclusion criteria

Exclusion criteria: 1. Patients with history of or nervous system diseases; 2. Patients with history of chronic pain; 3. Patients using cytochrome P450 modulators in less than 1 month; 4. Patients with any other conditions considered cannot be recruited.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;genotype;—

Secondary

MeasureTime frame
Simplifed Apfel risk score;PONV intensity scale;—

Countries

China

Contacts

Public ContactJiali Li

School of Pharmaceutical Sciences, Sun Yat-sen University

lijiali5@mail.sysu.edu.cn+86 020-39943034

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026